Federal Realty Powers Ahead on Hookup with Mercedes-Benz
Mercedes-Benz High-Power Charging and Federal Realty Investment Trust (NYSE:FRT) today announced a first-of-its-kind strategic agreement naming Mercedes-Benz the preferred EV charging provider across Federal Realty's best-in-class retail portfolio. “The collaboration,” referring to this morning’s news release, “establishes a scalable foundation to deliver an expected 500 new, ultra-fast charging stalls—accessible to all drivers, regardless of vehicle brand.”The initial rollout will begin with 20 locations across Federal's national portfolio, including Camelback Colonnade in Phoenix, AZ; Lawrence Park Shopping Center in Broomall, PA; and Shops at Pembroke Gardens in Pembroke Pines, FL. Each location will feature up to 10 charging stalls and Mercedes-Benz HPC signature 400 kW charging speeds, compatible with both CCS-1 and NACS equipped vehicles. The first locations are expected to come online in 2026.According to Mercedes North America CEO Andrew Cornelia, "EV drivers are looking for more than just fast charging, they want an experience that fits effortlessly into their lives. Federal Realty's national portfolio of properties meets this need in a meaningful way by placing chargers at destinations people already trust and enjoy. Together, we're tapping into a growing customer sentiment: charging isn't just about power — it's about place."FRT shares reached noon EDT in Wednesday trading higher $1.08, or 1.2%, to $95.26.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


